Navigation Links
Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
Date:11/7/2011

BASKING RIDGE, N.J., Nov. 7, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters highlighting positive substudy results of the Company's Phase 2b RADAR trial of REG1, Regado's proprietary anticoagulation system.  The posters will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium meeting on November 8, 2011 from 8:00-10:00 a.m. PST in San Francisco, CA.  

"The Phase 2b RADAR trial for REG1 has demonstrated a paradigm shift to provide physicians with a more effective option to control bleeding and ischemic events in ACS patients.  REG1 provides physicians the ability to titrate the intensity of anticoagulation according to specific patient needs, which are not currently met with existing drugs," said Dr. Mauricio Cohen, director of the cardiac catheterization laboratory at the University of Miami Miller School of Medicine and a lead investigator of the study, who will present the data.  "We're delighted to have the opportunity to share further analyses of these groundbreaking results among our peers."

The posters are titled "Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2b RADAR Trial" and "Access and non-Access Site Bleeding in Acute Coronary Syndrome Patients Treated with a Novel Actively Reversible Factor IXa Inhibitor: Results from the RADAR Trial."

REG1 is a two-component system consisting of pegnivacogin (a.k.a. RB006), a direct Factor IXa inhibitor, and anivamersen (a.k.a. RB007), its complementary active control agent.  The RADAR clinical trial demonstrated that REG1 provided nearly complete Factor IXa inhibition followed by 75% and 100% reversal, resulting in numerically lower rates of ischemic events when compared with heparin.  The res
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
2. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
3. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Regado Biosciences Establishes Medical Advisory Board
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
8. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
11. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... North Shore Towers, a luxury co-op community based just ... of the nation’s leading combined heating and power (CHP) systems ... CHP system. The original CHP system had been maintained since ... life of the plant, GI Energy was contracted to replace ... equipment, while maintaining continuous operation of the entire complex. ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: SNMX ... technologies to discover, develop, and commercialize novel flavor ... industries, today reported financial results for the second ... with $33.6 million in cash and highly liquid ... Senomyx achieved another important milestone with the regulatory ...
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... Gene Expression in Mammalian Cells , Use tag-specific antibodies ... Quinn Lu ,Stratagene , , The pCMV-Tag1 vector is ... cells. A target gene inserted into the pCMV-Tag1 vector,can ... ,(N-terminal, C-terminal or internal tagging), the ...
... with StrataPrep ,midiprep ... Jeff Braman ,Stratagene , Plasmid DNA was purified ... kit, a kit based on anion exchange chromatography, ... yields and,purity (as judged by 260-nm to 280-nm ...
... , , , ... , , Anuradha Mehta Donna Driscoll , ... Cleveland, OH , , , ... We chose Stratagenes Human Universal cDNA Library 1 , (HUCL) ...
Cached Biology Technology:An Epitope Tagging Vector for Gene Expression in Mammalian Cells 2An Epitope Tagging Vector for Gene Expression in Mammalian Cells 3An Epitope Tagging Vector for Gene Expression in Mammalian Cells 4An Epitope Tagging Vector for Gene Expression in Mammalian Cells 5An Epitope Tagging Vector for Gene Expression in Mammalian Cells 6Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 2Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 3Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 4Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 2Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 3Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 4Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 5Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 6
(Date:7/31/2014)... to help better identify and treat those with fibromuscular dysplasia ... of medium sized arteries in the body, which can restrict ... In a new report appearing in August 2014 issue of ... that that FMD may not be limited to the arteries ... abnormalities of bones and joints, as well as evidence that ...
(Date:7/31/2014)... was in full fury, raging swiftly from crown to ... of Yosemite National Park in California,s Sierra Nevada in ... began to turn, enacting a case study in the ... large, severe fires. , "When the Rim Fire hit ... been used as a management tool, rather than immediately ...
(Date:7/31/2014)... Most people are familiar with Hibiscus flowers- they ... where they are commonly planted in the landscape. ... - are endangered species. , Only a relatively ... aware of an equally beautiful and intriguing related ... literally "brother of Hibiscus". , Brother of Hibiscus ...
Breaking Biology News(10 mins):Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2
... the membrane of human liver cells that aids in cholesterol ... first step in hepatitis C infection, according to research at ... The cholesterol receptor offers a promising new target for anti-viral ... the researchers, whose findings were reported online in advance of ...
... has taken us a step closer to breeding hardier crops ... off attack from parasites. In a paper published in ... of the United States of America (PNAS), the researchers have ... Arabidopsis thaliana , or thale cress, by controlling an ...
... infants are helpless creatures that only blink, eat, cry ... studies indicate infant brains come equipped with knowledge of ... we study infant knowledge of the world by measuring ... Kristy vanMarle, an assistant professor in the Department of ...
Cached Biology News:Entry point for hepatitis C infection identified 2Improving crops from the roots up 2Babies are born with 'intuitive physics' knowledge, says MU researcher 2
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Biology Products: